The connection between kidney disease and diabetes is quite common and is often an alleged marker for the deteriorating condition of a diabetes patient. If you have been struggling around with your health, chances are that there could be a number of factors influencing your renal health, especially if your struggles with diabetes are ongoing.
A new study (R) conducted by the researchers from the Stanford Medicine has found and developed a drug which has been found to reduce the risks of kidney disease by a third in the people suffering from the type-2 diabetes.
This is possibly the very first time that something of this caliber has been developed and done to boast the overall well being of an individual, someone who is suffering from type-2 diabetes. Kidney failure is often times the worst of the conditions, impacting one’s health for the worse. The same is still under the ongoing tests to ensure the maximum of its benefits altogether.
Kenneth Mahaffey, MD, professor of medicine at the Stanford University School of Medicine who is also the co-principal investigator of the trial did suggest stating that this is the very first time that the researchers have a therapy for the patients suffering from the type-2 diabetes as well as chronic kidney disease that can in turn lead to kidney failure in the long run.
Mahaffey further claimed that the patients now have a potent and promising option to help conceal and protect them from one of the fatal consequences a Type-2 diabetic could face in their lifetime. This specific trial did comprise of around 4,401 participants from across 34 countries.
The drug, which has been named as canagliflozin, is an improved version of a nearly two decades old therapy which is currently the only version of treatment which has been approved for the kidney diseases altogether. In the conducted clinical trial, the drug was also found to have amazing impacts in reducing the risks associated with some of the major cardiovascular diseases and events.
Canagliflozin is the drug which has been found to have potent impacts on promoting better excretion of the glucose out of the kidneys in Type-2 Diabetes patients. The drug has been deemed safe and approved by the Food and Drug Administration to help lower the blood glucose in the patients suffering from Type-2 Diabetes.
The drug has already been approved to be administered to the Type-2 diabetes patients to regulate their blood glucose levels in the body.
What does the trial result suggest?
Vlado Perkovic, MBBS, PhD, executive director of The George Institute for Global Health Australia, who is also the lead author of the study did state saying that the patients suffering from type-2 diabetes are often at a very high risk of developing kidney diseases, heart attack or even stroke or death. The findings of this research are believed to help patients swerve those risks away with just once a day pill.
In people who participated in the trial were administered with the best of the care that was available for the kidney disease under some of the current guidelines – often termed as the rennin-Angiotensin-Aldosterone system blockade. In the conducted study, half the participants were provided with canagliflozin while the rest of the half was administered with a placebo.
The researchers observed that the participants who took canagliflozin were 30% less likely to end up developing kidney failure or even the cardiovascular disease. The rate of deaths due of risks of kidney failure was reduced by 34% while the cardiac issues were reduced by 31% altogether.
Sought after treatment
Yet another one of the factors that does stand out of the rest is the fact that people suffering from Type-2 diabetes have been vehemently waiting for a similar treatment to reduce the risks associated with the proper kidney functioning.
The main reason why diabetics are often at a heightened risk of developing kidney failure is mainly because of the fact that the high blood glucose tends to harm the blood vessels supplying the kidney. Apart from that, the high blood glucose levels in the body has been found to have adverse impacts in heightening the blood pressure, thus further affecting one’s health.
For the last 20 years, the doctors and the specialists have been blindly relying on the RAAS blockade to prevent any kind of deterioration of the kidney function in the diabetic patients. This treatment method is effective enough but the only issue with the same is the fact that it ends up lowering the blood pressure and even causes risks in causing renal failure in the long term.
This current finding is believed to be a breakthrough in several years when it does come down to regulating the risks associated with kidney disease and possible failure too. The drug does impose little to no side effects, thus making it a potent remedy to take a peek into.